Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ovarian Cancer - Prognosis
Lung Resistance Protein Predictive of Response and Prognosis
September 11th, 1995
A newly described protein, the lung resistance protein (Lrp), which is also called the p110 major vault protein, is indicative of response to chemotherapy and long-term prognosis in advanced ovarian carcinoma. Roughly 75 percent of the women diagnosed with ovarian cancer present with surgically incurable advanced disease. Chemotherapy after debulking surgery has increased the 5-year survival rate to 10-20 percent. Drug-resistant cancer cells that exist prior to or develop after treatment are likely to be responsible for the high rate of chemotherapy failure. However, previously discovered drug-resistance mechanisms have failed to be indicative of chemotherapy...
Source: Women's Health Weekly (1995-09-11)
|
